TABLE 2.
Comorbidities among patients receiving dasatinib, imatinib, or nilotinib for CML in the first-line setting between 2011 and 2019.
| All TKI (n = 1403) | dasatinib (n = 161) | imatinib (n = 865) | nilotinib (n = 377) | |
|---|---|---|---|---|
| Hypertension | 511 (36.4%) | 57 (35.4%) | 345 (39.9%) | 109 (28.9%) |
| Metabolic disorders | 267 (19.0%) | 34 (21.1%) | 179 (20.7%) | 54 (14.3%) |
| Diabetes mellitus | 208 (14.8%) | 31 (19.3%) | 138 (16.0%) | 39 (10.3%) |
| Ischemic heart disease | 187 (13.3%) | 17 (10.6%) | 130 (15.0%) | 40 (10.6%) |
| Other cancer | 159 (11.3%) | 20 (12.4%) | 108 (12.5%) | 31 (8.2%) |
| Pulmonary disease (lower tract) | 120 (8.6%) | 14 (8.7%) | 86 (9.9%) | 20 (5.3%) |
| Cerebral vascular accident | 105 (7.5%) | 10 (6.2%) | 73 (8.4%) | 22 (5.8%) |
| Arrythmiac condition (including AF) | 94 (6.7%) | 13 (8.1%) | 60 (6.9%) | 21 (5.6%) |
| Peripheral vascular disease | 82 (5.8%) | 10 (6.2%) | 55 (6.4%) | 17 (4.5%) |
| Congestive heart failure | 70 (5.0%) | N/A a | 49 (5.7%) | 12 (3.2%) |
| TOTAL WITH COMORBIDITIES | 750 (53.5%) | 86 (53.4%) | 507 (58.6%) | 157 (41.6%) |
CML: chronic myeloid leukemia, AF: atrial fibrillation.
a
Groups fewer than 10 are automatically cancelled by the National Health Insurance Fund (NHIF) due to data protection reasons.